Fewer Recalls With Consensus Double Read Mammograms

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 8
Volume 11
Issue 8

ATLANTA-Compared with independent double reading of mammograms, consensus double reading detects slightly more cancers while significantly decreasing recall rates, thereby minimizing the anxiety that women might experience from undergoing a second mammogram, Susan Harvey, MD, said at the 102nd Annual Meeting of the American Roentgen Ray Society (abstract 63).

ATLANTA—Compared with independent double reading of mammograms, consensus double reading detects slightly more cancers while significantly decreasing recall rates, thereby minimizing the anxiety that women might experience from undergoing a second mammogram, Susan Harvey, MD, said at the 102nd Annual Meeting of the American Roentgen Ray Society (abstract 63).

Dr. Harvey is assistant professor of radiology, University of Vermont College of Medicine, and lead author of the study.

With independent double reading of mammograms, two radiologists read each mammogram separately, and if either radiologist wants a recall of a woman for additional imaging studies, the recall takes place.

"Therefore, by the nature of it, it has to increase the recall rate," Dr. Harvey told ONI in an interview.

With consensus double reading, two radiologists read the mammogram and they both must agree on the findings and whether a recall is needed. If they disagree, a third radiologist is asked to review the case.

Over a 10-month period, Dr. Harvey and her colleagues performed consensus double reading of 15,985 screening mammograms, which led to 391 biopsies (2.4%). A total of 103 cancers were detected, and the second reader was responsible for detection of 10 of the cancers, a 9.7% increase in cancer detection. The recall rate was 13.2%.

In comparison, in their previous study of independent double reading, 25,369 mammograms read over 18 months led to 676 biopsies (2.7%). A total of 143 cancers were detected, and the second reader detected 11 of these cancers, for a 7.7% increase in detection. The recall rate was 14.2%.

Increased Cancer Detection Rate

The researchers conclude that double consensus reading increased the cancer detection rate by 9.7%, similar to the 7.7% increase seen with independent double reading, and, compared with independent double reading, decreased the recall rate by 7%.

Dr. Harvey noted that consensus double reading takes more radiologists’ time at the time of the double read, "but if it decreases the recall rate, then the overall time the radiologists spent on that group of women is decreased," she said. "A limitation is that you have to have enough staffing to provide this service." 

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.